Tag : CONFIRMED DISABILITY WORSENING

  • Early and continuous ofatumumab treatment offers durable outcomes over 7 years in pwRMS

    Ofatumumab, a fully human anti-CD20 monoclonal antibody, previously demonstrated superior efficacy versus teriflunomide in the phase 3 ASCLEPIOS I/II trials in people with relapsing multiple sclerosis (PwRMS). Earlier data had shown that ofatumumab maintained a favorable safety profile and sustained efficacy over 6 years of treatment. At the AAN Annual Meeting 2025, Dr. Gabriel Pardo from the Oklahoma Medical Research Foundation presented updated findings on the long-term safety and disability outcomes associated with continuous ofatumumab treatment for up to 7 years. The analysis also explored the impact of early versus delayed ofatumumab initiation, including outcomes in recently diagnosed (≤3 years) and treatment-naïve (RDTN) patients.

  • CONFERENCE UPDATE
    Tolebrutinib slows disability progression in nrSPMS: Results from the phase 3 HERCULES trial

    The phase 3 HERCULES trial demonstrates that tolebrutinib reduces disability progression in non-relapsing secondary progressive multiple sclerosis (nrSPMS) by 31%, offering hope for this underserved population.